Pharmaceutical Manufacturer — First Ind AS Audit: ₹2.3 Crore Revenue Restatement, 11 Undisclosed RPTs, Clean Opinion
A ₹87 crore pharma exporter navigating mandatory Ind AS adoption for the first time. A material revenue restatement on CIF exports, 11 undisclosed related-party transactions, and near-expiry inventory with no provision policy — every issue resolved before the report date. Unmodified opinion delivered.
Three material issues on the first year of Ind AS reporting.
The company crossed the Ind AS threshold in FY 2023–24, making FY 2024–25 the first statutory audit under Indian Accounting Standards — which also required restating FY 2023–24 comparatives. Three issues emerged during audit planning and fieldwork. First, the company had been recognising export revenue on CIF-term shipments at the factory gate (dispatch) rather than at the destination port (control transfer under Ind AS 115), resulting in a ₹2.3 crore restatement. Second, a review of all payments above ₹5 lakh to non-group entities surfaced 11 transactions totalling ₹1.4 crore with a company in which a director’s spouse held a majority shareholding — all commercially arm’s-length but never disclosed as related-party transactions, not subject to audit committee approval, and requiring retrospective Section 188 shareholder ratification. Third, 14 pharmaceutical batches were approaching use-by dates with no formal provision policy in place.
How we executed the engagement.
Ind AS 115 Revenue Restatement
Identified all year-end export shipments on CIF terms by pulling shipping documentation, bill of lading dates, destination port arrival confirmations, and contract Incoterms. Calculated the ₹2.3 crore restatement, restated FY 2023–24 comparatives, adjusted the opening balance sheet, and drafted a clear restatement note that met disclosure requirements without creating unnecessary alarm.
RPT Identification, Disclosure & Ratification
Prepared a full transaction listing with dates, amounts, and the director’s spouse relationship. Convened the audit committee. Board’s legal advisors confirmed retrospective shareholder ratification required under Section 188. Resolution passed at the AGM. All 11 transactions disclosed under Ind AS 24 with complete detail before the audit report date.
Pharma Inventory Provision Policy
Developed a tiered near-expiry provision policy: 25% for stock within 90 days of expiry, 100% for stock within 30 days. Applied to 14 near-date batches — total provision impact ₹68 lakh. Recorded in the accounts before sign-off.
CARO 2020 — 21-Clause Completion
All 21 CARO 2020 clauses completed with supporting workpapers. The term loan utilisation clause required particular attention: a portion of the manufacturing facility term loan had been used to fund working capital. Disclosed with an explanation of the circumstance and the regularisation steps taken.
IFC Deficiency Documentation
Three Internal Financial Control deficiencies documented in the management letter: fixed asset capitalisation timing; vendor payment approval controls (approvals below delegated authority); and R&D expenditure classification (process development costs eligible for Ind AS 38 capitalisation being expensed). All three communicated to management and the audit committee; none rose to material weakness level.
The capabilities we brought to bear.
Ind AS 115 Revenue Recognition
CIF export revenue analysis: identifying in-transit shipments at year-end, computing the restatement, restating comparatives, and drafting the disclosure note.
Ind AS 24 Related-Party Compliance
Full RPT identification across all non-group payments; disclosure preparation; audit committee briefing; Section 188 ratification coordination.
Pharmaceutical Inventory Provisions
Near-expiry batch identification and tiered provision policy design — first formal expiry provision in the company’s history.
CARO 2020 Reporting
21-clause completion including cross-utilisation disclosure and regularisation narrative for term loan variance.
IFC Deficiency Management
Below-material-weakness deficiency identification, management letter drafting, and remediation tracking.
The numbers that matter.
The results we delivered.
Every issue we found — the revenue restatement, the undisclosed related-party payments, the inventory gaps — was addressed before we signed the report. That’s how a material first-year transition audit ends with an unmodified opinion.
